


Supplementary File

Material and Methods

Supplementary Figure 1. Flowchart with steps following the recruited participants

Neuropsychological Instruments

The **Verbal Categorical Fluency Test**^{1 2} is a verbal fluency task encompassing a semantic category (animals). This test was introduced as part of the Boston Diagnostic Aphasia Examination and can be used separately to evaluate the language, semantic memory, and cognitive flexibility. This task consists of recalling the highest number of animals in 60 seconds, and its score refers to the total amount of words about the topic (animals).

The **Phonemic Verbal Fluency Test**³ consists of a naming words task that aims at recollecting words beginning with the letters F, A, and S, respectively, with a one-minute

threshold for each letter. The final score is the sum of the words spoken correctly in each trial. This task evaluates language, semantic memory, and executive function.

The **Logical Memory subtest** from the Wechsler Memory Scale (WMS-R)^{4 5} is a worldwide test used to evaluate immediate and delayed episodic memory. The examiner verbally presents two stories, and each story includes 25 pertinent pieces of information. Subjects are required to recall details of each story immediately after its presentation and again after 20 minutes.

The **Trail Making Test (TMT)**^{6 7} is subdivided into two parts. Part A assesses processing speed and visual search in a task that requires ascending connection order of 25 numbers, randomly arranged. Part B evaluates alternating attention and cognitive flexibility in a task associated with shifting rules in an ascending sequence of 25 numbers. A training stage is applied to both parts.

The **Beck Depression Inventory (BDI-II)**⁸ is a self-administered scale used for screening the severity of depressive symptoms. It consists of a standard multiple-choice questionnaire with 21 questions containing four items each. The total score ranges from 0 to 63 and the levels of severity thresholds follow 0-13 for minimal or no depression; 14-19 for mild depression; 20-28 for moderate depression; and 29-63 for severe depression symptoms.

The **Beck Anxiety Inventory (BAI)**⁹ is also a self-administered scale for screening the severity of anxiety symptoms. This scale consists of 21 items with descriptive statements of physical and subjective symptoms of anxiety. The total score ranges from 0 to 63, allowing the characterization of intensity levels according to the following cutoffs: 0-10 for minimal or asymptomatic anxiety symptoms; 11-19 as mild anxiety; 20-30 as moderate anxiety; and 31-63 as severe anxiety symptoms.

The **Chalder Fatigue Scale (CFQ-11)**¹⁰ questionnaire was used to assess the severity of fatigue. The participants answer 11 items on a 4-point scale (0-3). The global score range from 0-33. The scale can be used to separate “cases” and “non-cases”, based on a binary fatigue score ranging from 0-11. According to the binary system, scores of 4 or more are considered “cases” with fatigue¹¹.

We used the **Epworth sleepiness scale (ESS)** to estimate excessive daytime sleepiness (EDS). It is a self-report questionnaire with 8 situations involving daily activities. The

final global scores range from 0-24; the diagnosis of EDS is suggested for those with scores higher than 10¹².

MRI Protocol (3T Philips-Achieva) designed for Post-COVID individuals:

- Axial diffusion weighted image (DWI) with acquisition voxel sizes of 1.51x1.95x3 mm³ reconstructed with 0.9x0.9x3 mm³, 55 slices, gap = 0.3 mm, TR = 3776 ms, TE = 94 ms, flip angle = 90° and FOV = 230x230 mm².
- Axial susceptibility weighted image (SWI) with acquisition voxel sizes of 0.6x0.6x2 mm³ reconstructed with 0.34x0.34x1 mm³, 142 slices, no gap, TR = 42 ms, 6 echos, first echo = 7.19 ms and echospacing = 6.2 ms, flip angle = 17° and FOV = 230x189 mm².
- Sagittal T1 3D WI with isotropic voxels of 1 mm, acquired in the sagittal plane, 1 mm thick, no gap, flip angle=8°, TR=7.0 ms, TE=3.2 ms, matrix=240x240, FOV=240x240 mm²
- Sagittal T2-3D fluid attenuated inversion recovery image (FLAIR) with isotropic voxels of 1.2 mm, reconstructed with 0.5x0.5x0.6 mm³, 300 slices, gap = 0.6 mm, TR=10000 ms, TI = 2680 ms, TE=276 ms, 2 averages (sampling averages), FOV = 250x250 mm²
- Resting-state: Echo planar images (EPI) with voxel sizes of 3x3x3 mm³, acquired on the axial plane with 40 slices, no gap, flip angle=90°, TR=2 s, TE=30 ms in a 6-minute scan resulting in 180 dynamics and FOV = 240x240 mm².
- DWI/DTI: Diffusion tensor image (multiple diffusion direction images) with acquisition voxel sizes of 2x2x2 mm³ reconstructed with 1x1x2 mm³, 70 slices,

no gap, TR = 8500 ms, TE = 61 ms, flip angle 90°; 32 gradient directions; no averages; max b-factor = 1000 s/mm², FOV = 256x256 mm².

Functional connectivity

We performed the functional connectivity study using the UF²C toolbox (<https://www.lniunicamp.com/uf2c>) within SPM12 (<http://www.fil.ion.ucl.ac.uk/spm/>, using MATLAB 2019b) ¹³. For this analysis, we initially included 132 subjects (55 controls and 77 patients). From the original group of 87, one individual was excluded due to previous large hemangioma and three due to movements' artifacts. The images preprocessing followed the UF²C standard pipeline and briefly, was based on functional image realignment, normalization to the MNI-space (Montreal Neurologic Institute Standard template), co-registration with T1-WI image, framewise displacement (FD), and the derivative variance (DVAR) estimation (head movement parameters) and smoothing with a kernel of 6x6x6 mm (FWHM). Additionally, structural images segmentation, modulation, and normalization (MNI space). After the initial preprocessing, the functional images were detrended (to remove MR linear trend), band-pass filtered (0.008-0.1 Hz), and regressed for censoring vectors (framewise displacement (FD) >0.5mm), white matter (WM), and CSF average signal, and for six realignment parameters.


- We performed the following quality control procedures:

Using the estimated individual FD, we excluded three subjects (2 controls and 1 patient) who presented abnormal values for FD (severe upper outliers [values higher than one interquartile range (IQR) regarding the volunteers mean value]). One control was excluded due to an image error. After this procedure, the average FD for the control group was 0.180 mm and 0.175 mm for the patients' group. No statistical difference


was found between groups (FD, $p = 0.716$, Mann-Whitney test). Aiming to guarantee the intersubject FOV reproducibility, we used the UF²C outlier tool with the post-processed functional images: individual binary masks were created with the post-processed functional mean image of each volunteer, then, the tool identified any subjects with an abnormal (higher than $1.5 \cdot \text{IQR}$) number of voxels that were outside the group averaged mask. The final number of subjects included in the analysis was 128 [52 controls (34 women, median age of 30 years, range 25-63) and 76 patients (59 women, median age of 37, range 21-65)].

Supplementary results

Supplementary Figure 2. The graph shows the reported symptoms in the COVID-19 acute phase of 87 patients.



Supplementary Figure 3. The graph shows the reported symptoms of 87 patients approximately 54 days after the COVID-19 acute stage.



Supplementary Table 1. Description of participants with abnormalities in the neurological examination.		
Gender	Age (Decade of Life)	Neurological finding
Male	40-49	Spastic paraparesis; myalgia.
Male	70-79	Somnolence (Glasgow Coma Scale 14 (EOR4 VR 4 M 6)); poverty of speech; upper limb strength 3/5 and lower limb strength 2/5
Female	50-59	Paresthesia in the lower left face; myalgia
Female	40-49	Dysdiadocokinesia
Female	30-39	Nystagmus; dizziness (benign paroxysmal positional vertigo (BPPV) like)
Male	20-29	Distal hypopalesthesia in the four limbs
Female	50-59	Hyperreflexia in the left superior limb
Male	20-29	Hypoesthesia of the right superior limb
Male	50-59	Paraparesis, cerebellar ataxia
Male	50-59	Intention and rest tremor; cerebellar ataxia
Female	60-69	Sensory ataxia; Tromner sign in the right hand; slowness of right hand

Supplementary Table 2. Neuropsychological evaluation of post-COVID 19 patients (78 individuals)		
	Median	Interval
Age	36	[18–70]
Education (years)	15	[6–24]
BDI-II Score	6.5	[0–36]
BAI Score	6	[0–45]
CFQ-11 Score (59 subjects)	16	[0–32]
ESS (59 subjects)	9	[0–21]
Neuropsychological tests		
	Median of Z-score	Interval (min-max)
Phonological Fluency	-0.98	[-2.76 to 2.37]

Semantic Fluency	0.41	[-1.52 to 2.73]
Logical Memory (Immediate recall)	-0.63	[-2.26 to 1.96]
Logical Memory (delayed recall)	-0.3	[-2.38 to 1.57]
Trail Test		
A	-0.74	[-7.05 to 1.38]
B	-1.1	[-5.55 to 1.25]
BDI: Beck depression inventory; BAI: Beck anxiety inventory; CFQ: Chalder Fatigue Questionnaire; ESS: Epworth Sleepiness Scale;		

DTI RESULTS

Fractional Anisotropy (FA)

Supplementary Table 3. For FA, after a multivariate analysis of variance (MANOVA), we did not identify significant interaction between tracts \times groups (Pillai's Trace = 0.022, $F_{[4,128]} = 0.732$, $p = 0.572$, partial $\eta^2 = 0.022$, Observed Power = 0.231). Data presented in the table show the trend for higher FA values for the patients.

FA -Tract		Mean	Std. Error	95% Confidence Interval	
				Low. Bound	Upp. Bound
Body CC	Controls	0.574	0.002	0.570	0.578
	Patients	0.578	0.002	0.574	0.582
Fornix	Controls	0.453	0.003	0.447	0.459
	Patients	0.456	0.003	0.451	0.461
Genu CC	Controls	0.534	0.002	0.529	0.538
	Patients	0.538	0.002	0.534	0.542
Splenum CC	Controls	0.580	0.002	0.577	0.584
	Patients	0.583	0.002	0.580	0.586

Comparison (MANOVA) of FA in midline tracts of post-COVID patients and controls. Besides no statistical difference, post-COVID patients present a trend of higher FA values in midline tracts.

FA: Fractional Anisotropy; CC: Corpus Callosum

Supplementary Table 4. For FA, after a repeated measures analysis of variance (ANOVA), we did not identify significant interaction between bilateral tracts \times groups (Pillai's Trace = 0.011, $F_{[5,127]} = 0.295$, $p = 0.915$, partial $\eta^2 = 0.011$; Observed Power = 0.122).

FA - Tract			Mean	Std. Error	95% Confidence Interval	
					Low. Bound	Upp. Bound
Controls	Left	Cingulum	0.517	0.003	0.510	0.523
		Corticospinal	0.614	0.002	0.610	0.619
		IFO	0.562	0.003	0.557	0.568
		ILF	0.458	0.002	0.454	0.462
		Parahippocampal	0.447	0.003	0.442	0.452
		Uncinate	0.489	0.003	0.483	0.495
	Right	Cingulum	0.514	0.003	0.508	0.520
		Corticospinal	0.613	0.002	0.609	0.618
		IFO	0.564	0.003	0.559	0.570

		ILF	0.450	0.002	0.446	0.454
		Parahippocampal	0.445	0.003	0.439	0.451
		Uncinate	0.488	0.003	0.482	0.494
Patients	Left	Cingulum	0.520	0.003	0.514	0.525
		Corticospinal	0.616	0.002	0.613	0.620
		IFO	0.563	0.002	0.558	0.567
		ILF	0.457	0.002	0.454	0.461
		Parahippocampal	0.446	0.002	0.441	0.450
		Uncinate	0.490	0.003	0.485	0.495
	Right	Cingulum	0.519	0.003	0.514	0.524
		Corticospinal	0.613	0.002	0.609	0.616
		IFO	0.564	0.002	0.559	0.568
		ILF	0.450	0.002	0.447	0.453
		Parahippocampal	0.444	0.002	0.440	0.449
		Uncinate	0.487	0.003	0.482	0.493
<i>Comparison (Repeated Measures ANOVA) of FA in bilateral tracts of post-COVID patients and controls. Besides no statistical difference, post-COVID patients present a trend of higher FA values in bilateral tracts.</i>						
<i>FA: Fractional Anisotropy; IFO: Inferior Fronto-Occipital Fasciculus; ILF: Inferior Longitudinal Fasciculus</i>						

Mean Diffusivity (MD)

Supplementary Table 5. For MD, after a MANOVA, we did not identify significant interaction between tracts \times groups (Pillai's Trace = 0.007, $F_{[4,128]} = 0.237$, $p=0.917$, partial $\eta^2 = 0.007$, Observed Power = 0.100).

MD - Tract		Mean	Std. Error	95% Confidence Interval	
				Low. Bound	Upp. Bound
Body CC	Controls	0.0005095	0.0000041	0.0005013	0.0005176
	Patients	0.0005078	0.0000034	0.0005011	0.0005146
Fornix	Controls	0.0010973	0.0000136	0.0010704	0.0011243
	Patients	0.0010994	0.0000113	0.0010771	0.0011217
Genu CC	Controls	0.0005250	0.0000045	0.0005162	0.0005338
	Patients	0.0005205	0.0000037	0.0005132	0.0005278
Splenium CC	Controls	0.0005393	0.0000049	0.0005296	0.0005490
	Patients	0.0005383	0.0000041	0.0005303	0.0005464
<i>Comparison (MANOVA) of MD in midline tracts of post-COVID patients and controls. There is no statistical difference of MD between post-COVID patients and controls.</i>					
<i>MD: Mean Diffusivity; CC: Corpus Callosum</i>					

Supplementary Table 6. For MD, after a repeated measures ANOVA, we did not identify significant interaction between bilateral tracts \times groups (Pillai's Trace = 0.020, $F_{[5,127]} = 0.520$, $p=0.760$, partial $\eta^2 = 0.020$; Observed Power = 0.188).

MD - Tract			Mean	Std. Error	95% Confidence Interval	
					Low. Bound	Upp. Bound
Controls	Left	Cingulum	0.0007288	0.0000035	0.0007218	0.0007357
		Corticospinal	0.0008247	0.0000038	0.0008172	0.0008323
		IFO	0.0007970	0.0000047	0.0007877	0.0008063
		ILF	0.0007597	0.0000032	0.0007535	0.0007660
		Parahippocampal	0.0008309	0.0000062	0.0008186	0.0008432
		Uncinate	0.0007776	0.0000042	0.0007693	0.0007859
	Right	Cingulum	0.0007315	0.0000036	0.0007244	0.0007386
		Corticospinal	0.0008265	0.0000038	0.0008191	0.0008340
		IFO	0.0007986	0.0000047	0.0007892	0.0008079
		ILF	0.0007564	0.0000032	0.0007501	0.0007628
		Parahippocampal	0.0008315	0.0000066	0.0008185	0.0008445
		Uncinate	0.0007783	0.0000045	0.0007694	0.0007871
Patients	Left	Cingulum	0.0007238	0.0000029	0.0007180	0.0007295
		Corticospinal	0.0008191	0.0000032	0.0008128	0.0008253
		IFO	0.0007962	0.0000039	0.0007885	0.0008039
		ILF	0.0007542	0.0000026	0.0007490	0.0007594
		Parahippocampal	0.0008366	0.0000051	0.0008265	0.0008468
		Uncinate	0.0007765	0.0000035	0.0007696	0.0007834
	Right	Cingulum	0.0007232	0.0000030	0.0007173	0.0007290
		Corticospinal	0.0008266	0.0000031	0.0008205	0.0008328
		IFO	0.0007945	0.0000039	0.0007868	0.0008023
		ILF	0.0007525	0.0000027	0.0007472	0.0007578
		Parahippocampal	0.0008383	0.0000054	0.0008276	0.0008491
		Uncinate	0.0007785	0.0000037	0.0007712	0.0007859
<p><i>Comparison (Repeated Measures ANOVA) of MD in bilateral tracts of post-COVID patients and controls. There is no statistical difference of MD between post-COVID patients and controls.</i></p> <p><i>MD: Mean Diffusivity; IFO: Inferior Fronto-Occipital Fasciculus; ILF: Inferior Longitudinal Fasciculus</i></p>						

Radial Diffusivity (RD)

Supplementary Table 7. For RD, after a MANOVA, we did not identify significant interaction between tracts \times groups (Pillai's Trace = 0.006, $F_{[4,128]} = 0.182$, $p=0.947$, partial $\eta^2 = 0.006$, Observed Power = 0.088).

RD - Tract		Mean	Std. Error	95% Confidence Interval	
				Low. Bound	Upp. Bound
Body CC	Controls	0.0005095	0.0000041	0.0005013	0.0005176
	Patients	0.0005078	0.0000034	0.0005011	0.0005146
Fornix	Controls	0.0010973	0.0000136	0.0010704	0.0011243
	Patients	0.0010994	0.0000113	0.0010771	0.0011217
Genu CC	Controls	0.0005250	0.0000045	0.0005162	0.0005338
	Patients	0.0005205	0.0000037	0.0005132	0.0005278
Splenius CC	Controls	0.0005393	0.0000049	0.0005296	0.0005490
	Patients	0.0005383	0.0000041	0.0005303	0.0005464

Comparison (MANOVA) of RD in midline tracts of post-COVID patients and controls. Besides no statistical difference, post-COVID patients present a trend of lower RD values in midline tracts.
 RD: Radial Diffusivity; CC: Corpus Callosum

Supplementary Table 8. For RD, after a repeated measures ANOVA, we did not identify significant interaction between tracts \times groups (Pillai's Trace = 0.022, $F_{[5,127]} = 0.580$, $p=0.715$, partial $\eta^2 = 0.022$, Observed Power = 0.207).

RD - Tract		Mean	Std. Error	95% Confidence Interval		
				Low. Bound	Upp. Bound	
Controls	Left	Cingulum	0.0005013	0.0000037	0.0004941	0.0005086
		Corticospinal	0.0005110	0.0000039	0.0005032	0.0005187
		IFO	0.0005194	0.0000040	0.0005115	0.0005273
		ILF	0.0005605	0.0000030	0.0005546	0.0005664
		Parahippocampal	0.0006206	0.0000055	0.0006098	0.0006314
		Uncinate	0.0005557	0.0000045	0.0005468	0.0005646
	Right	Cingulum	0.0005052	0.0000037	0.0004978	0.0005126
		Corticospinal	0.0005130	0.0000039	0.0005053	0.0005206
		IFO	0.0005193	0.0000041	0.0005111	0.0005275
		ILF	0.0005631	0.0000030	0.0005572	0.0005690
		Parahippocampal	0.0006220	0.0000060	0.0006103	0.0006338
		Uncinate	0.0005568	0.0000048	0.0005474	0.0005662
		Cingulum	0.0004966	0.0000030	0.0004906	0.0005026

Patients	Left	Corticospinal	0.0005056	0.0000032	0.0004992	0.0005120
		IFO	0.0005194	0.0000033	0.0005129	0.0005259
		ILF	0.0005575	0.0000025	0.0005526	0.0005624
		Parahippocampal	0.0006261	0.0000045	0.0006171	0.0006350
		Uncinate	0.0005549	0.0000037	0.0005475	0.0005623
	Right	Cingulum	0.0004967	0.0000031	0.0004906	0.0005028
		Corticospinal	0.0005134	0.0000032	0.0005070	0.0005197
		IFO	0.0005179	0.0000034	0.0005111	0.0005247
		ILF	0.0005606	0.0000025	0.0005557	0.0005655
		Parahippocampal	0.0006282	0.0000049	0.0006184	0.0006379
		Uncinate	0.0005579	0.0000039	0.0005501	0.0005657

Comparison (Repeated Measures ANOVA) of RD in bilateral tracts of post-COVID patients and controls. Besides no statistical difference, post-COVID patients present a trend of lower RD values in bilateral tracts.

RD: Radial Diffusivity; IFO: Inferior Fronto-Occipital Fasciculus; ILF: Inferior Longitudinal Fasciculus

Axial Diffusivity (AD)

Supplementary Table 9. For AD, after a MANOVA, we did not identify significant interaction between tracts \times groups (Pillai's Trace = 0.010, $F_{[4,128]} = 0.334$, $p=0.855$, partial $\eta^2 = 0.010$, Observed Power = 0.124).

AD - Tract		Mean	Std. Error	95% Confidence Interval	
				Low. Bound	Upp. Bound
Body CC	Controls	0.0013508	0.0000079	0.0013352	0.0013664
	Patients	0.0013582	0.0000065	0.0013453	0.0013711
Fornix	Controls	0.0021418	0.0000191	0.0021040	0.0021797
	Patients	0.0021501	0.0000158	0.0021188	0.0021814
Genu CC	Controls	0.0012870	0.0000064	0.0012743	0.0012997
	Patients	0.0012855	0.0000053	0.0012750	0.0012960
Splenium CC	Controls	0.0014630	0.0000085	0.0014462	0.0014798
	Patients	0.0014696	0.0000070	0.0014557	0.0014835

Comparison (MANOVA) of AD in midline tracts of post-COVID patients and controls. Besides no statistical difference, post-COVID patients present a trend of lower AD values in midline tracts.

AD: Axial Diffusivity; CC: Corpus Callosum

Supplementary Table 10. For AD, after a repeated measures ANOVA, we did not identify significant interaction between tracts \times groups (Pillai's Trace = 0.020, $F_{[5,127]} = 0.517$, $p=0.763$, partial $\eta^2 = 0.020$, Observed Power = 0.187).

AD - Tract			Mean	Std. Error	95% Confidence Interval	
					Low. Bound	Upp. Bound
Controls	Left	Cingulum	0.0011835	0.0000059	0.0011718	0.0011952
		Corticospinal	0.0014523	0.0000048	0.0014427	0.0014619
		IFO	0.0013522	0.0000079	0.0013366	0.0013679
		ILF	0.0011581	0.0000047	0.0011489	0.0011674
		Parahippocampal	0.0012517	0.0000085	0.0012350	0.0012684
		Uncinate	0.0012214	0.0000050	0.0012115	0.0012312
	Right	Cingulum	0.0011841	0.0000058	0.0011727	0.0011955
		Corticospinal	0.0014539	0.0000048	0.0014444	0.0014635
		IFO	0.0013570	0.0000076	0.0013419	0.0013721
		ILF	0.0011431	0.0000047	0.0011339	0.0011523
		Parahippocampal	0.0012506	0.0000087	0.0012334	0.0012678
		Uncinate	0.0012213	0.0000051	0.0012112	0.0012314
Patients	Left	Cingulum	0.0011783	0.0000049	0.0011687	0.0011880
		Corticospinal	0.0014460	0.0000040	0.0014381	0.0014539
		IFO	0.0013495	0.0000066	0.0013366	0.0013625
		ILF	0.0011476	0.0000039	0.0011400	0.0011553
		Parahippocampal	0.0012576	0.0000070	0.0012438	0.0012714
		Uncinate	0.0012198	0.0000041	0.0012117	0.0012279
	Right	Cingulum	0.0011758	0.0000048	0.0011664	0.0011853
		Corticospinal	0.0014531	0.0000040	0.0014452	0.0014610
		IFO	0.0013479	0.0000063	0.0013354	0.0013604
		ILF	0.0011363	0.0000038	0.0011287	0.0011439
		Parahippocampal	0.0012586	0.0000072	0.0012444	0.0012728
		Uncinate	0.0012197	0.0000042	0.0012114	0.0012281
<p><i>Comparison (Repeated Measures ANOVA) of AD in midline tracts of post-COVID patients and controls. Besides no statistical difference, post-COVID patients present a trend of lower AD values in bilateral tracts.</i></p> <p><i>AD: Axial Diffusivity; IFO: Inferior Fronto-Occipital Fasciculus; ILF: Inferior Longitudinal Fasciculus</i></p>						

FUNCTIONAL CONNECTIVITY RESULTS

Supplementary Table 11. T-test of patients and controls

cluster	cluster	Peak			
p(FDR-corr)	Cluster Size	T	p(unc)	x,y,z {mm}	Region of Interest

0.084	31	4.535	<0.001	30	-70	26	Right Superior/Middle Occipital Gyrus
0.063	40	4.264	<0.001	-44	4	2	Left Anterior Insula
<i>T-test of Posterior Cingulate Cortex (a Default Mode Network hub) functional connectivity map of post-COVID patients and controls. Observe the trend forward a higher connectivity of Posterior Cingulate Cortex and Left Insula and Right Occipital cortex.</i>							

Supplementary Table 12. Results from the regression between maps of DMN and scores of Fatigue.

Cluster		Peak					
p(FDR-corr)	Cluster Size	T	p(unc)	x,y,z {mm}			Region of Interest
0.016	199	4.582	<0.001	-46	-64	36	Left Angular Gyrus
		3.897	<0.001	-44	-58	26	Left Angular Gyrus
0.006	57	4.294	<0.001	42	-56	22	Right Angular Gyrus
<i>Linear regression of Posterior Cingulate Cortex (a Default Mode Network hub) functional connectivity with fatigue in post-COVID patients. Higher levels of fatigue correlate with a higher connectivity of Posterior Cingulate Cortex with Bilateral Angular Gyri.</i>							
<i>FDRc=57</i>							

Supplementary Table 13. Results from the regression between maps of DMN and scores of excessive Sleepiness.

Cluster		Peak					
p(FDR-corr)	Cluster Size	T	p(unc)	x,y,z {mm}			Region of Interest
0.016	54	5.052	<0.001	-8	-20	18	Left Thalamus
		3.614	<0.001	-8	-28	16	Left Thalamus
0.025	42	4.753	<0.001	-22	10	0	Left Putamen
<i>Linear regression of Posterior Cingulate Cortex (a Default Mode Network hub) functional connectivity with sleepiness in post-COVID patients. Higher levels of sleepiness correlate with a higher connectivity of Posterior Cingulate Cortex with Left Thalamus and Left Putamen..</i>							
<i>FDRc=42</i>							

Supplementary Table 14. Online questionnaire - SECTION 1 / 2

We are researchers from the Department of Neurology (School of Medical Sciences / UNICAMP) and from the Department of Biology (UNICAMP), and we are studying the effects of coronavirus in the central nervous system.

This questionnaire will help us to understand how people are recovering themselves after the infection by the new coronavirus. Our complete project includes a magnetic resonance, neurological and cognitive examination (memory, language...). If it is possible for you to answer this questionnaire, we would be very grateful.

Principal investigator: Prof. Clarissa Lin Yasuda (CRM 94104)

Contact: neurocovid@hc.unicamp.br (19) 99768-7517

*Required

E-mail address*	(Your e-mail)			
Name*	(Your answer)			
Age*	(Your Answer)			
Gender	Male	Female	I prefer not to answer	Other:
Phone	(Your answer)			
City / State	(Your answer)			

<p>Do you have any association with UNICAMP?</p> <p>(Are you a student, professor or worker at UNICAMP?)</p>	Yes	No		
<p>Date of diagnosis (COVID infection)*</p>	Date of confirmation (with a test)			
<p>Diagnostic Method</p> <p>What was the confirmation's method of the Covid diagnosis?</p>	PCR (Swab)	Antibodies (Blood test / Quick test)	Antibody + PCR	Other:
<p>Treatment</p> <p>Select the type of treatment for the COVID infection</p>	Home	Hospital - Infirmary	Hospital – Intensive Care Unit	
<p>Symptoms of acute infection*</p> <p>Describe the symptoms you presented during the acute period (in the hospital or individual isolation, in case you had the treatment done). Select all the relevant symptoms.</p>	Shortness of breath	Tiredness / Fatigue	Fever	
	Olfactory changes	Headache	Taste changes	
	No symptoms	Other: _____		

<p>Symptoms in the first month after hospital discharge / quarantine</p> <p>Describe the symptoms in the period after the hospital discharge or after the end of individual isolation (If you had your treatment at home). Select all the relevant symptoms.</p>	Shortness of breath	Tiredness / Fatigue	Fever
	Olfactory changes	Headache	Taste changes
	No symptoms	Other:	

After section 1, continue to section 2

SECTION 2 / 2

<p>SYMPTOMS AFTER COVID INFECTION</p> <p>In this section, we will talk about the symptoms that occurred after the recovering of COVID 19 infection.</p>			
<p>Frequent Post-Covid Symptoms</p> <p>Check the symptoms that had after the</p>	Headache	Olfactory changes	Taste changes
		Shortness of breath	Fever

infection, but may not necessarily persisted up to now.	Tiredness / Fatigue		
	Somnolence during the day	Memory problems	Difficulties with daily activities
	Motor Difficulties	Coordination difficulties	I do not present any symptom
	Other: _____		
Current Post-Covid Symptoms Check the currently persistent symptoms you had after the infection	Headache	Olfactory changes	Taste changes
	Tiredness / Fatigue	Shortness of breath	Fever
	Somnolence during the day	Memory problems	Difficulties with daily activities

	Motor Difficulties	Coordination difficulties	I do not present any symptom
	Other: _____		
Would you like to describe any more symptoms?	(Your answer)		
May we contact you?	Yes	No	
If yes, do you have a preferred medium of contact?	Registered Email	Registered Phone	Other

References

1. Brucki SD, et al. Dados normativos para o teste de Fluência Verbal categoria animais em nosso meio. *Arq neuropsiquiatria* 1997;55(1):56-61.
2. Brucki SM, Rocha MS. Category fluency test: effects of age, gender and education on total scores, clustering and switching in Brazilian Portuguese-speaking subjects. *Braz J Med Biol Res* 2004;37(12):1771-7. doi: 10.1590/s0100-879x2004001200002
3. Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. *Arch Clin Neuropsychol* 1999;14(2):167-77.
4. Bolognani SAP, Miranda MC, Martins M, et al. Development of alternative versions of the Logical Memory subtest of the WMS-R for use in Brazil. *Dement Neuropsychol* 2015;9(2):136-48. doi: 10.1590/1980-57642015dn92000008 [published Online First: 2015/04/01]
5. Wechsler D. Manual for the Wechsler Memory Scale - Revised. San Antonio: TX: The Psychological Corporation 1987.

6. Campanholo KR, Romão MA, Machado MAR, et al. Performance of an adult Brazilian sample on the Trail Making Test and Stroop Test. *Dement Neuropsychol* 2014;8(1):26-31. doi: 10.1590/s1980-57642014dn81000005 [published Online First: 2014/01/01]
7. Strauss E SE, Spreen O. A compendium of neuropsychological tests. Administration, norms and commentary. New York: Oxford University Press 2006.
8. Gomes-Oliveira MH, Gorenstein C, Lotufo Neto F, et al. Validation of the Brazilian Portuguese version of the Beck Depression Inventory-II in a community sample. *Braz J Psychiatry* 2012;34(4):389-94. doi: 10.1016/j.rbp.2012.03.005
9. Cunha JA. *Manual of Beck scales in Portuguese (Manual da versão em português das Escalas Beck)*. São Paulo: Casa do Psicólogo. ed, 2001.
10. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. *J Psychosom Res* 1993;37(2):147-53. doi: 10.1016/0022-3999(93)90081-p
11. Jackson C. The Chalder Fatigue Scale (CFQ 11). *Occup Med (Lond)* 2015;65(1):86. doi: 10.1093/occmed/kqu168
12. Bertolazi AN, Fagundes SC, Hoff LS, et al. Portuguese-language version of the Epworth sleepiness scale: validation for use in Brazil. *J Bras Pneumol* 2009;35(9):877-83. doi: 10.1590/s1806-37132009000900009
13. de Campos BM, Coan AC, Lin Yasuda C, et al. Large-scale brain networks are distinctly affected in right and left mesial temporal lobe epilepsy. *Hum Brain Mapp* 2016;37(9):3137-52. doi: 10.1002/hbm.23231 [published Online First: 2016/05/03]